These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32371478)

  • 1. Inactivation of
    Gstalder C; Liu D; Miao D; Lutterbach B; DeVine AL; Lin C; Shettigar M; Pancholi P; Buchbinder EI; Carter SL; Manos MP; Rojas-Rudilla V; Brennick R; Gjini E; Chen PH; Lako A; Rodig S; Yoon CH; Freeman GJ; Barbie DA; Hodi FS; Miles W; Van Allen EM; Haq R
    Cancer Discov; 2020 Sep; 10(9):1296-1311. PubMed ID: 32371478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
    He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
    Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
    Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
    Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
    Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.
    Ishizuka JJ; Manguso RT; Cheruiyot CK; Bi K; Panda A; Iracheta-Vellve A; Miller BC; Du PP; Yates KB; Dubrot J; Buchumenski I; Comstock DE; Brown FD; Ayer A; Kohnle IC; Pope HW; Zimmer MD; Sen DR; Lane-Reticker SK; Robitschek EJ; Griffin GK; Collins NB; Long AH; Doench JG; Kozono D; Levanon EY; Haining WN
    Nature; 2019 Jan; 565(7737):43-48. PubMed ID: 30559380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
    Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
    Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
    Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
    Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
    Xiao Y; Yin C; Wang Y; Lv H; Wang W; Huang Y; Perez-Losada J; Snijders AM; Mao JH; Zhang P
    Mol Oncol; 2018 Jun; 12(6):883-895. PubMed ID: 29633504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent insight into the role of FBXW7 as a tumor suppressor.
    Yumimoto K; Nakayama KI
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):1-15. PubMed ID: 32113998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.
    Yeh CH; Bellon M; Wang F; Zhang H; Fu L; Nicot C
    Mol Cancer; 2020 Sep; 19(1):139. PubMed ID: 32907612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15
    Dominguez CX; Müller S; Keerthivasan S; Koeppen H; Hung J; Gierke S; Breart B; Foreman O; Bainbridge TW; Castiglioni A; Senbabaoglu Y; Modrusan Z; Liang Y; Junttila MR; Klijn C; Bourgon R; Turley SJ
    Cancer Discov; 2020 Feb; 10(2):232-253. PubMed ID: 31699795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response.
    Choi H; Kwon J; Cho MS; Sun Y; Zheng X; Wang J; Bouker KB; Casey JL; Atkins MB; Toretsky J; Han C
    Cancer Res; 2021 Jul; 81(13):3607-3620. PubMed ID: 33941613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells.
    Shimizu H; Takeishi S; Nakatsumi H; Nakayama KI
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
    Wang Q; Xie B; Liu S; Shi Y; Tao Y; Xiao D; Wang W
    Front Immunol; 2021; 12():773168. PubMed ID: 35003090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of FBXW7 loss of function in human cancers.
    Fan J; Bellon M; Ju M; Zhao L; Wei M; Fu L; Nicot C
    Mol Cancer; 2022 Mar; 21(1):87. PubMed ID: 35346215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7.
    Ding J; Zhao Z; Song J; Luo B; Huang L
    Acta Biochim Biophys Sin (Shanghai); 2018 Jun; 50(6):597-604. PubMed ID: 29701752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
    Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
    Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of Fbxw7 Impairs Development of and Induces Heterogeneous Tumor Formation in the Mouse Mammary Gland.
    Onoyama I; Nakayama S; Shimizu H; Nakayama KI
    Cancer Res; 2020 Dec; 80(24):5515-5530. PubMed ID: 33234509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.